• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

    4/21/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email

    PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.

    Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

    An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

    About Amicus Therapeutics

    Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at www.amicusrx.com, and follow on X and LinkedIn.

    CONTACT:

    Investors:

    Amicus Therapeutics

    Andrew Faughnan

    Vice President, Investor Relations

    [email protected]

    (609) 662-3809

    Media:

    Amicus Therapeutics

    Diana Moore

    Head of Global Corporate Affairs and Communications

    [email protected]

    (609) 662-5079

    FOLD–G



    Primary Logo

    Get the next $FOLD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    7/17/2025$108.00Equal-Weight → Overweight
    Morgan Stanley
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    More analyst ratings

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcglynn Margaret G was granted 20,414 shares, increasing direct ownership by 29% to 91,550 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    6/6/25 4:59:48 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Raab Michael was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    6/6/25 4:58:48 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sblendorio Glenn was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    6/6/25 4:58:02 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amicus Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Amicus Therapeutics from Equal-Weight to Overweight and set a new price target of $108.00

    7/17/25 7:51:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

    12/13/24 7:53:22 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Amicus Therapeutics with a new price target

    Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

    9/6/24 7:39:36 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    SEC Filings

    View All

    SEC Form 10-Q filed by Amicus Therapeutics Inc.

    10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    7/31/25 4:02:39 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    7/31/25 7:01:06 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Amicus Therapeutics Inc.

    S-8 - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    6/5/25 4:46:04 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

    NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and eff

    8/6/25 8:30:00 AM ET
    $AMGN
    $CTOR
    $FOLD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

    Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2025. "We delivered strong second quarter growth of 18%, marking the seventeenth consecutive quarter of doub

    7/31/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

    PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.co

    7/21/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Leadership Updates

    Live Leadership Updates

    View All

    Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

    Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

    8/21/23 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

    6/14/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

    Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

    5/6/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:00:58 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amicus Therapeutics Inc.

    SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 11:37:23 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:31:54 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Financials

    Live finance-specific insights

    View All

    Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

    Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2025. "We delivered strong second quarter growth of 18%, marking the seventeenth consecutive quarter of doub

    7/31/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

    PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.co

    7/21/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

    1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and c

    5/1/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care